Novo Holdings A/S’s Edgewise Therapeutics EWTX Stock Holding History

Novo Holdings A/S’s Portfolio EWTX Stock Details EWTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$169M	Hold	5,350,000	–	–	13.65%	1
2025 Q4	$133M	Hold	5,350,000	–	–	10.31%	2
2025 Q3	$86.8M	Hold	5,350,000	–	–	5.59%	5
2025 Q2	$70.1M	Hold	5,350,000	–	–	4.95%	6
2025 Q1	$118M	Buy	5,350,000 +350,000	+7%	+$9.18M	8.95%	3
2024 Q4	$134M	Sell	5,000,000 -549,900	-10%	-$17.5M	8.08%	4
2024 Q3	$148M	Sell	5,549,900 -794,530	-13%	-$15.8M	7.36%	4
2024 Q2	$114M	Buy	+6,344,430	New	+$111M	6.16%	6
2024 Q1	–	Sell	-6,071,703	Closed	-$66.4M	–	36
2023 Q4	$66.4M	Hold	6,071,703	–	–	4.1%	8
2023 Q3	$34.8M	Hold	6,071,703	–	–	2.57%	15
2023 Q2	$47.1M	Hold	6,071,703	–	–	3.64%	8
2023 Q1	$40.5M	Hold	6,071,703	–	–	2.67%	13
2022 Q4	$54.3M	Hold	6,071,703	–	–	3.39%	10
2022 Q3	$59.7M	Buy	6,071,703 +484,496	+9%	+$4.9M	2.85%	13
2022 Q2	$44.5M	Hold	5,587,207	–	–	2.19%	15
2022 Q1	$54.2M	Hold	5,587,207	–	–	2.86%	11
2021 Q4	$85.4M	Hold	5,587,207	–	–	4.04%	7
2021 Q3	$92.7M	Hold	5,587,207	–	–	4.8%	6
2021 Q2	$119M	Hold	5,587,207	–	–	5.29%	6
2021 Q1	$182M	Buy	+5,587,207	New	+$181M	7.5%	2

Other funds holding EWTX

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Novo Holdings A/S's EWTX Position: Q1 2026 in Review

Novo Holdings A/S held its Edgewise Therapeutics (EWTX) position steady in Q1 2026 at 5,350,000 shares worth $169M. The position accounts for 13.65% of the portfolio, ranked #1.

Novo Holdings A/S first reported a position in EWTX in Q1 2021 and has held it in 20 quarters since. The position peaked at $182M in Q1 2021. 214 funds tracked by Wall St. Rank hold EWTX as of Q1 2026.

Novo Holdings A/S held 5,350,000 shares of Edgewise Therapeutics worth $169M as of Q1 2026.
Novo Holdings A/S left its Edgewise Therapeutics share count unchanged in Q1 2026.
Edgewise Therapeutics made up 13.65% of Novo Holdings A/S's portfolio in Q1 2026, its #1 holding.
Novo Holdings A/S first reported a position in Edgewise Therapeutics in Q1 2021 and has held it in 20 quarters since.
Novo Holdings A/S's Edgewise Therapeutics position peaked at $182M in Q1 2021.
214 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q1 2026.

Based on Novo Holdings A/S's 13F filing for Q1 2026, filed 15 May 2026.